Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes
Background: Diabetic peripheral neuropathy (DPN), the most common microvascular complication of type-2 diabetes mellitus (T2DM), results in nontraumatic lower-limb amputations. When DPN is not detected early, disease progression is irreversible. Thus, biomarkers for diagnosing DPN are needed. Method...
Guardado en:
Autores principales: | , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
SAGE Publishing
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0a3da1dc74b347fc96d228c08c8d0645 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:0a3da1dc74b347fc96d228c08c8d0645 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:0a3da1dc74b347fc96d228c08c8d06452021-12-01T07:33:19ZNeuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes2040-623110.1177/20406223211041936https://doaj.org/article/0a3da1dc74b347fc96d228c08c8d06452021-09-01T00:00:00Zhttps://doi.org/10.1177/20406223211041936https://doaj.org/toc/2040-6231Background: Diabetic peripheral neuropathy (DPN), the most common microvascular complication of type-2 diabetes mellitus (T2DM), results in nontraumatic lower-limb amputations. When DPN is not detected early, disease progression is irreversible. Thus, biomarkers for diagnosing DPN are needed. Methods: We analyzed three data sets of T2DM DPN: two for mouse models (GSE70852 and GSE34889) and one for a human model (GSE24290). We found common differentially expressed genes (DEGs) in the two mouse data sets and validated them in the human data set. To identify the phenotypic function of the DEGs, we overexpressed them in zebrafish embryos. Clinical information and serum samples of T2DM patients with and without DPN were obtained from the Korea Biobank Network. To assess the plausibility of DEGs as biomarkers of DPN, we performed an enzyme-linked immunosorbent assay. Results: Among the DEGs, only NPY and SLPI were validated in the human data set. As npy is conserved in zebrafish, its mRNA was injected into zebrafish embryos, and it was observed that the branches of the central nervous system became thicker and the number of dendritic branches increased. Baseline characteristics between T2DM patients with and without DPN did not differ, except for the sex ratio. The mean serum NPY level was higher in T2DM patients with DPN than in those without DPN ( p = 0.0328), whereas serum SLPI levels did not differ ( p = 0.9651). Conclusion: In the pathogenesis of DPN, NPY may play a protective role in the peripheral nervous system and may be useful as a biomarker for detecting T2DM DPN.Noo Ree ChoYeuni YuChang-Kyu OhDai Sik KoKyungjae MyungYoonsung LeeHee Sam NaYun Hak KimSAGE PublishingarticleTherapeutics. PharmacologyRM1-950ENTherapeutic Advances in Chronic Disease, Vol 12 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Therapeutics. Pharmacology RM1-950 |
spellingShingle |
Therapeutics. Pharmacology RM1-950 Noo Ree Cho Yeuni Yu Chang-Kyu Oh Dai Sik Ko Kyungjae Myung Yoonsung Lee Hee Sam Na Yun Hak Kim Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes |
description |
Background: Diabetic peripheral neuropathy (DPN), the most common microvascular complication of type-2 diabetes mellitus (T2DM), results in nontraumatic lower-limb amputations. When DPN is not detected early, disease progression is irreversible. Thus, biomarkers for diagnosing DPN are needed. Methods: We analyzed three data sets of T2DM DPN: two for mouse models (GSE70852 and GSE34889) and one for a human model (GSE24290). We found common differentially expressed genes (DEGs) in the two mouse data sets and validated them in the human data set. To identify the phenotypic function of the DEGs, we overexpressed them in zebrafish embryos. Clinical information and serum samples of T2DM patients with and without DPN were obtained from the Korea Biobank Network. To assess the plausibility of DEGs as biomarkers of DPN, we performed an enzyme-linked immunosorbent assay. Results: Among the DEGs, only NPY and SLPI were validated in the human data set. As npy is conserved in zebrafish, its mRNA was injected into zebrafish embryos, and it was observed that the branches of the central nervous system became thicker and the number of dendritic branches increased. Baseline characteristics between T2DM patients with and without DPN did not differ, except for the sex ratio. The mean serum NPY level was higher in T2DM patients with DPN than in those without DPN ( p = 0.0328), whereas serum SLPI levels did not differ ( p = 0.9651). Conclusion: In the pathogenesis of DPN, NPY may play a protective role in the peripheral nervous system and may be useful as a biomarker for detecting T2DM DPN. |
format |
article |
author |
Noo Ree Cho Yeuni Yu Chang-Kyu Oh Dai Sik Ko Kyungjae Myung Yoonsung Lee Hee Sam Na Yun Hak Kim |
author_facet |
Noo Ree Cho Yeuni Yu Chang-Kyu Oh Dai Sik Ko Kyungjae Myung Yoonsung Lee Hee Sam Na Yun Hak Kim |
author_sort |
Noo Ree Cho |
title |
Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes |
title_short |
Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes |
title_full |
Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes |
title_fullStr |
Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes |
title_full_unstemmed |
Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes |
title_sort |
neuropeptide y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes |
publisher |
SAGE Publishing |
publishDate |
2021 |
url |
https://doaj.org/article/0a3da1dc74b347fc96d228c08c8d0645 |
work_keys_str_mv |
AT nooreecho neuropeptideyapotentialtheranosticbiomarkerfordiabeticperipheralneuropathyinpatientswithtype2diabetes AT yeuniyu neuropeptideyapotentialtheranosticbiomarkerfordiabeticperipheralneuropathyinpatientswithtype2diabetes AT changkyuoh neuropeptideyapotentialtheranosticbiomarkerfordiabeticperipheralneuropathyinpatientswithtype2diabetes AT daisikko neuropeptideyapotentialtheranosticbiomarkerfordiabeticperipheralneuropathyinpatientswithtype2diabetes AT kyungjaemyung neuropeptideyapotentialtheranosticbiomarkerfordiabeticperipheralneuropathyinpatientswithtype2diabetes AT yoonsunglee neuropeptideyapotentialtheranosticbiomarkerfordiabeticperipheralneuropathyinpatientswithtype2diabetes AT heesamna neuropeptideyapotentialtheranosticbiomarkerfordiabeticperipheralneuropathyinpatientswithtype2diabetes AT yunhakkim neuropeptideyapotentialtheranosticbiomarkerfordiabeticperipheralneuropathyinpatientswithtype2diabetes |
_version_ |
1718405395935920128 |